Summary
Majority of AI-generated claims are not supported by the label. A subset aligns with label language (notably Mucinex D containing guaifenesin and pseudoephedrine, pseudoephedrine BP risk, and consult if hypertension). Overall alignment is poor.
Category Scores
Accurate Statements
Mucinex D contains guaifenesin and pseudoephedrine.
Active ingredients; Drug Facts; Warnings and Precautions
Pseudoephedrine can spike blood pressure.
Warnings and Precautions; Contraindications
Mucinex D is not safe with blood pressure medications; avoid.
Warnings and Precautions; Contraindications
Plain Mucinex contains guaifenesin.
Active ingredients; Drug Facts
Mucinex DM contains guaifenesin and dextromethorphan.
Active ingredients; Drug Facts
Check labels and consult your doctor or pharmacist if you have uncontrolled hypertension.
Warnings and Precautions
Unsupported Statements
Most Mucinex products (guaifenesin-based expectorants) do not raise blood pressure.
Label does not state that guaifenesin universally does not affect blood pressure; BP risk concerns primarily with pseudoephedrine-containing products.
Most Mucinex products are generally safe with antihypertensive drugs like ACE inhibitors, beta-blockers, or diuretics.
Label does not provide broad compatibility with all antihypertensives.
Guaifenesin alone has no known interactions with these meds.
Label does not enumerate no interactions; absence of listed interactions is not proof of no interactions.
Avoid Mucinex DM or Mucinex Fast-Max with dextromethorphan (cough suppressant), as it can slightly raise blood pressure in some people.
BP-raising warning with dextromethorphan is not standard label; label warnings focus on drowsiness and interactions.
Dextromethorphan can slightly raise blood pressure in some people.
BP elevation not a stated label warning for dextromethorphan.
Mucinex DM is usually safe with BP meds, but monitor BP.
Label does not state general BP-med compatibility; BP monitoring is not universal label directive.
Mucinex D should be avoided.
Label does not give blanket avoidance; contraindications exist for certain conditions.
Guaifenesin has no direct interactions with lisinopril.
No explicit universal no-interaction claim in label.
Guaifenesin has no direct interactions with losartan.
No explicit universal no-interaction claim in label.
Guaifenesin has no direct interactions with metoprolol.
No explicit universal no-interaction claim in label.
Guaifenesin has no direct interactions with amlodipine.
No explicit universal no-interaction claim in label.
Pseudoephedrine in Mucinex D interacts with all by raising BP.
Label mentions BP elevation with decongestants but not 'interacts with all' language.
Robitussin contains plain guaifenesin.
Robitussin label not provided; not part of Mucinex label evidence.
Contradictions
Important Omissions
No explicit statement on interactions of guaifenesin with specific antihypertensive medications beyond general BP considerations; multiple antihypertensives are listed but interactions are not detailed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
BP-related risk exists for pseudoephedrine-containing products; no high-risk signals beyond that
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Many BP-related statements made about Mucinex products are not supported by label language.
Suggested Improvement
Limit BP-related claims to label-supported warnings (e.g., pseudoephedrine-containing products may raise BP; consult with clinician for hypertension). Avoid asserting universal 'no interactions' for guaifenesin with BP meds.